On November 28, 2023 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, reported that it had five abstracts accepted as poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 5-9 at the Henry B. Gonzalez Convention Center in San Antonio (Press release, Sermonix Pharmaceuticals, NOV 28, 2023, View Source [SID1234638047]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Three posters delve into clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies. One assesses baseline genomic alterations and the activity of lasofoxifene, Sermonix’s investigational novel endocrine therapy, and Eli Lilly and Company’s CDK4/6 inhibitor abemaciclib during the ELAINE-2 study. A second poster addresses pharmacokinetics of lasofoxifene as a monotherapy and in combination with abemaciclib. The third poster is a trial-in-progress update on ELAINE-3, which is studying the efficacy and safety of lasofoxifene in combination with abemaciclib in treating locally advanced or ER+/HER2- mBC with an ESR1 mutation.

The other two posters address the results of Sermonix’s third ESR1 and Quality of Life Survey (EQUALS 3), which was developed to help inform practicing oncologists about patients’ understanding of ESR1 mutations and the quality of life for metastatic breast cancer (mBC) patients. One poster addresses patient-provider communication challenges with respect to side effects of mBC treatments, and the second discusses how minimizing treatment toxicity and side effects impacts quality of life for ER+/HER2- mBC patients.

"Sermonix looks forward to updating our peers at SABCS 2023 about our growing understanding of lasofoxifene as a monotherapy and combination therapy, our initiated ELAINE-3 study, and our continuing work to learn more about how metastatic breast cancer impacts patient quality of life," said Dr. David Portman, Sermonix founder and chief executive officer. "We are committed to investigating lasofoxifene’s efficacy in combating metastatic breast cancer, as well as observing its impacts on vaginal and sexual health, all issues that affect patients greatly."

Poster sessions details are as follows:

Poster Title: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE-2 study
Poster ID: P02-14-09
Date: Wednesday, Dec. 6, 2023
Time: 5-7 p.m. CT
Poster Title: Pharmacokinetics (PK) of lasofoxifene (LAS) monotherapy and combined with abemaciclib (Abema)
Poster ID: P03-18-05
Date: Thursday, Dec. 7, 2023
Time: 12-2 p.m. CT
Poster Title: Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE-3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation
Poster ID: P01-18-12
Date: Wednesday, Dec. 6, 2023
Time: 12-2 p.m. CT
Poster Title: Patient (pt)-provider communication challenges about side effects/ from metastatic breast cancer (mBC) treatments]
Poster ID: P03-12-05
Date: Thursday, Dec. 7, 2023
Time: 12-2 p.m. CT
Poster Title: Minimization of treatment toxicity/side effects and their impact on quality of life (QoL) in patients (pts) with ER+/HER2- metastatic breast cancer (mBC)
Poster ID: P03-12-06
Date: Friday, Dec. 8, 2023
Time: 12-2 p.m. CT
To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit View Source For more information about the ELAINE studies, visit View Source

About Lasofoxifene
Lasofoxifene is an investigational novel endocrine therapy in clinical development which has demonstrated robust target engagement as an ESR1 antagonist in the breast, particularly in the presence of ESR1 mutations. Lasofoxifene has demonstrated anti-tumor activity as monotherapy and in combination with a CDK4/6 inhibitor in Phase 2 studies and has unique tissue selectivity distinguishing it from other current and investigational endocrine therapies, with beneficial effects seen on vagina and bone in previous clinical studies. Lasofoxifene, which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ:LGND), has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a novel targeted and tissue selective oral endocrine therapy could, if approved, play a critical role in the precision medicine treatment of advanced ER+ breast cancer.